These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 3938633

  • 1. [Superficial bladder tumors. Preliminary results of a prospective study comparing endovesical BCG, adriamycin and thio-tepa].
    Martínez-Piñeiro JA, de la Peña J, Hidalgo L, Cisneros J, Jiménez León J, Machuca J, Perdices C.
    Arch Esp Urol; 1985; 38(6):545-53. PubMed ID: 3938633
    [No Abstract] [Full Text] [Related]

  • 2. Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group Study.
    Lamm DL, Crissmann J, Blumenstein B, Crawford ED, Montie J, Scardino P, Grossman HB, Stanisic T, Smith J, Sullivan J.
    Prog Clin Biol Res; 1989; 310():263-70. PubMed ID: 2672016
    [No Abstract] [Full Text] [Related]

  • 3. [Preliminary results of a randomized study between intravesical adriamycin and thio-tepa in the treatment of superficial tumors of bladder].
    Allona Moncada A, Santos García Vaquero I, Polo Villar G, Díaz González R, González Martín M, Zuloaga Gómez A, Martínez Torres JL, Rodríguez Alvarez J, Duarte Vázquez JJ, Megino López JF.
    Arch Esp Urol; 1984; 37(2):113-22. PubMed ID: 6431914
    [No Abstract] [Full Text] [Related]

  • 4. BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
    Fisher HA.
    Prog Clin Biol Res; 1989; 310():275-83. PubMed ID: 2505271
    [No Abstract] [Full Text] [Related]

  • 5. [Comparative study of thiotepa, adriamycin and cisplatin in the prophylaxis of recurrence of superficial bladder carcinoma in a group of 217 patients].
    Llopis B, Gallego J, Boronat F, Moreno B, Mompó JA, Jiménez JF.
    Actas Urol Esp; 1986; 10(4):225-30. PubMed ID: 3092589
    [No Abstract] [Full Text] [Related]

  • 6. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
    Debruyne FM, van der Meijden AP, Schreinemachers LM, Geboers AD, Franssen MP, van Leeuwen MJ, Steerenberg PA, de Jong WH, Ruitenberg EJ.
    Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
    [No Abstract] [Full Text] [Related]

  • 7. Intravesical chemotherapy.
    Prout GR.
    Prog Clin Biol Res; 1984; 162B():125-50. PubMed ID: 6438639
    [No Abstract] [Full Text] [Related]

  • 8. Management of superficial bladder carcinoma with BCG. Long term follow-up.
    Martínez-Piñeiro JA.
    Prog Clin Biol Res; 1984; 162B():335-45. PubMed ID: 6438642
    [No Abstract] [Full Text] [Related]

  • 9. Resume of selected studies of the National Bladder Cancer Collaborative Group A and new protocols.
    Prout GR, Kopp J.
    Prog Clin Biol Res; 1984; 162B():397-427. PubMed ID: 6438644
    [No Abstract] [Full Text] [Related]

  • 10. [Comparative study of treatments of bladder carcinoma: TUR, thiotepa or BCG].
    Rodrigues Netto Júnior N, Caserta Lemos G.
    Arch Esp Urol; 1981; 34(5):369-74. PubMed ID: 6800309
    [No Abstract] [Full Text] [Related]

  • 11. [Coadjuvant action of chemotherapy and immunotherapy in the carcinoma of the bladder].
    Rodrigues-Netto Júnior N, Napoli F, Lemos GC.
    Rev Paul Med; 1979; 94(3-4):51-3. PubMed ID: 121486
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of superficial bladder tumors in a controlled trial with thio-TEPA versus adriamycin.
    Horn Y, Eidelman A, Walach N, Yuval E, Markowitz A.
    J Surg Oncol; 1984 Sep; 27(1):67-9. PubMed ID: 6434883
    [Abstract] [Full Text] [Related]

  • 13. Effects of local chemotherapy and immunotherapy on the recurrence and progression of superficial bladder cancer.
    Novak R, Kern J, Fister H, Trnski D, Dimanovski J, Kraus O.
    Eur Urol; 1988 Sep; 14(5):367-70. PubMed ID: 3139417
    [Abstract] [Full Text] [Related]

  • 14. BCG therapy of superficial bladder tumors.
    Herr HW.
    Prog Clin Biol Res; 1989 Sep; 303():369-74. PubMed ID: 2674999
    [No Abstract] [Full Text] [Related]

  • 15. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes].
    Iturralde Codina A, Beyríe Tamayo W, Gozá León F, Muñoz YI.
    Arch Esp Urol; 2004 Sep; 57(6):606-18. PubMed ID: 15382436
    [Abstract] [Full Text] [Related]

  • 16. Adjuvant intravesical therapy for superficial bladder cancer.
    Batts CN.
    Ann Pharmacother; 1992 Oct; 26(10):1270-6. PubMed ID: 1421654
    [Abstract] [Full Text] [Related]

  • 17. BCG in the management of superficial bladder cancer.
    Robinson MR.
    Prog Clin Biol Res; 1985 Oct; 185B():161-6. PubMed ID: 3898140
    [No Abstract] [Full Text] [Related]

  • 18. [Comparative study of adriamycin and thiotepa in the chemoprophylaxis of superficial bladder tumors].
    Salinas Sánchez AS, Moreno Avilés J, Pérez Albacete M, Salmerón Lopez-Rua J, Guardiola Más A, Server Falgas G.
    Actas Urol Esp; 1989 Oct; 13(2):99-102. PubMed ID: 2499166
    [Abstract] [Full Text] [Related]

  • 19. The role of intravesical thiotepa in the management of superficial bladder cancer. National Bladder Cancer Collaborative Group A.
    Cancer Res; 1977 Aug; 37(8 Pt 2):2916-7. PubMed ID: 406040
    [Abstract] [Full Text] [Related]

  • 20. [Thio-tepa in the prevention of recurrences of papillary bladder tumors].
    Kierfeld G, Mellin P.
    Z Urol Nephrol; 1973 Aug; 66(8):569-72. PubMed ID: 4204011
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.